Clinical trials: Resistant Major Depression
Depression
Buprenorphine for Late-Life Treatment Resistant Depression
The goals of this pilot study are to gather data about the safety and clinical effect of low-dose buprenorphine in older adults with treatment resistant depression.
- Trial name
- BUILD (NCT01071538)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Treatment Resistant Major Depressive Disorder
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy…
- Trial name
- ASCERTAINTRD (NCT02977299)
- Testing
- Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
- Where
- 13 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Treatment Resistant Depression
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an…
- Trial name
- RUBY (NCT00789854)
- Testing
- Quetiapine XR, Lithium carbonate, SSRI/Venlafaxine
- Where
- 106 sites in Australia, Austria and 11 more
- Volunteers
- 688 people
- Sponsor
- AstraZeneca
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Treatment Resistant Depression, Major Depressive Disorder
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression
- Trial name
- OPTIMUM (NCT02960763)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 5 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
Electroconvulsive therapy (ECT), is considered the most effective treatment for severe treatment resistant major depressive disorder (MDD), but it requires about 3 weeks of treatments and can cause considerable acute deficits in…
- Trial name
- NCT01260649
- Testing
- ketamine, IV Saline, ECT
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD).
- Trial name
- NCT00633399
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Optimization of IV Ketamine for Treatment Resistant Depression
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD.
- Trial name
- NCT00768430
- Testing
- Ketamine, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Baylor College of Medicine